iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
– Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 […]
iTeos Therapeutics Announces $120 Million Registered Direct Offering
– Led by existing investors RA Capital Management and Boxer Capital– Purchase price of $17.50 represents a premium of approximately […]
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 […]
Aqua Metals Joins $4.99 Million DOE Grant Project to Pioneer Domestic Critical Mineral Supply Chain
RENO, Nev., May 10, 2024 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium-ion battery recycling […]
Telos Corporation Announces First Quarter Results Above Guidance: Reports $29.6 Million of Revenue, 37.0% GAAP Gross Margin, and 42.2% Cash Gross Margin
Reports First Quarter Results Above High End of Guidance Range on Key Financial Metrics Delivered $29.6 Million of Revenue, Reflecting […]
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused […]
Creative Realities Reports Fiscal 2024 First Quarter Results
LOUISVILLE, Ky., May 10, 2024 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a […]
Smart for Life to Attend Vitafoods Europe 2024: Positioned to Identify Strategic Partnerships and Potential Acquisitions
MIAMI, May 10, 2024 (GLOBE NEWSWIRE) — Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a […]
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
— Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial […]
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
BOSTON, May 10, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights […]
